MedTrace Logo

Effect of Dapagliflozin on Interleukin 10 in Sepsis

NCT07206160 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2025-10-03

No results posted yet for this study

Summary

The goal of this observational study is to learn about the long-term effects of dapagliflozin as anti-inflammatory agents to improve organ dysfunction and decrease mortality on patients of both genders ageing 18 years or above with sepsis.

1ry Outcome: The anti-inflammatory effect of dapagliflozin in patients with sepsis evaluated by: Effect on inflammatory markers (IL-10).

2ry Outcomes:

1. Severity of sepsis evaluated by the SOFA score.
2. Prognostic value of HDL compared to IL-10 for multi organ failure and death in septic patients and their correlation to the severity of sepsis.
3. ICU mortality \&hospital length stay.

Conditions

Sponsors & Collaborators

  • Minia University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-10-01
Completion
2026-11-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07206160 on ClinicalTrials.gov